Results 291 to 300 of about 41,710 (302)

Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor–induced peritracheal edema

Journal of Allergy and Clinical Immunology, 2007
James Brian Byrd, Mark D Does
exaly  

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

Expert Opinion on Investigational Drugs, 2010
Carolyn F Deacon, Jens J Holst Dmsci
exaly  

Dipeptidyl Peptidase‐4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation

Journal of the American Heart Association, 2017
Taichi Ikedo, Manabu Minami, Hiroharu Kataoka   +2 more
exaly  

Inhibition of dipeptidyl peptidase IV and xanthine oxidase by amino acids and dipeptides

Food Chemistry, 2013
Alice B Nongonierma, Catherine Mooney, Denis C Shields   +2 more
exaly  

Sitagliptin: A Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Annals of Pharmacotherapy, 2006
exaly  

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

Clinical Therapeutics, 2008
exaly  

Dipeptidyl peptidase-4 (DPP-4) inhibitors

British Journal of Cardiology, 2017
openaire   +1 more source

Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin

Diabetes, Obesity and Metabolism, 2007
exaly  

Dipeptidyl‐Peptidase‐4 Inhibitor, Alogliptin, Attenuates Arterial Inflammation and Neointimal Formation After Injury in Low‐Density Lipoprotein (LDL) Receptor‐Deficient Mice

Journal of the American Heart Association, 2015
exaly  

Chapter-07 Dipeptidyl Peptidase-4 Inhibitors

2014
openaire   +1 more source